

**Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial**

Prospective, open-label phase 2a pilot trial. Patients with refractory mod-severe UC biologic-experienced received 10 or 20 daily hyperbaric oxygen therapy (HBOT) sessions (2.4 atmospheres absolute, 120min/day) while continuing stable therapy.

Primary endpoints: Composite clinical and endoscopic response at week 12

**Results: N=16**

- At week 12, composite response was achieved 6/16 (38%) of the overall patients: 2/8 (25%) of those who received 10-sessions and 4/8 (50%) of those who received 20-sessions.
- Improvements in clinical, endoscopic and IUS parameters were observed in both groups.

**Conclusion:**

HBOT is a well-tolerated adjunctive therapy in refractory UC, which improved clinical outcomes and perfusion kinetics. These findings support further evaluation in a randomized, dose-optimized trial.

**Clinical and endoscopic response at week 12**